A novel direct co-culture assay analyzed by multicolor flow cytometry reveals context- and cell type-specific immunomodulatory effects of equine mesenchymal stromal cells.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
25
10
2018
accepted:
12
06
2019
entrez:
28
6
2019
pubmed:
28
6
2019
medline:
25
2
2020
Statut:
epublish
Résumé
The immunomodulatory potential of multipotent mesenchymal stromal cells (MSC) provides a basis for current and future regenerative therapies. In this study, we established an approach that allows to address the effects of pro-inflammatory stimulation and co-culture with MSC on different specific leukocyte subpopulations. Equine peripheral blood leukocyte recovery was optimized to preserve all leukocyte subpopulations and leukocyte activation regimes were evaluated. Allogeneic labeled equine adipose-derived MSC were then subjected to direct co-culture with either non-stimulated, concanavalin A (ConA)-activated or phosphate 12-myristate 13-acetate and ionomycin (PMA/I)-activated leukocytes. Subsequently, production of the cytokines interferon-γ (IFN- γ), interleukin-1 (IL-1) and tumor necrosis factor-α (TNF-α) and presence of FoxP3 were determined in specific cell populations using multicolor flow cytometry. Prostaglandin E2 (PGE2) was measured in the supernatants. ConA-stimulation induced mild activation of leukocytes, whereas PMA/I-stimulation led to strong activation. In T cells, PMA/I promoted production of all cytokines, with no distinct suppressive effects of MSC. However, increased numbers of CD25/FoxP3-positive cells indicated that MSC supported regulatory T cell differentiation in PMA/I-activated leukocyte cultures. MSC also reduced numbers of cytokine-producing B cells and granulocytes, mostly irrespective of preceding leukocyte activation, and reversed the stimulatory effect of ConA on IFN-γ production in monocytes. Illustrating the possible suppressive mechanisms, higher numbers of MSC produced IL-10 when co-cultured with non-stimulated or ConA-activated leukocytes. This was not observed in co-culture with PMA/I-activated leukocytes. However, PGE2 concentration in the supernatant was highest in the co-culture with PMA/I-activated leukocytes, suggesting that PGE2 could still mediate modulatory effects in strongly inflammatory environment. These context- and cell type-specific modulatory effects observed give insight into the interactions between MSC and different types of immune cells and highlight the roles of IL-10 and PGE2 in MSC-mediated immunomodulation. The approach presented could provide a basis for further functional MSC characterization and the development of potency assays.
Identifiants
pubmed: 31247035
doi: 10.1371/journal.pone.0218949
pii: PONE-D-18-30852
pmc: PMC6597077
doi:
Substances chimiques
Interleukin-1
0
Interleukin-10
130068-27-8
Interferon-gamma
82115-62-6
Dinoprostone
K7Q1JQR04M
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0218949Déclaration de conflit d'intérêts
This work has no affiliation to the company Vaxxinova GmbH diagnostics. There are no competing interests. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
Blood. 2011 May 5;117(18):4826-35
pubmed: 21389316
Front Immunol. 2017 Aug 28;8:1042
pubmed: 28894451
Immunol Lett. 2016 Sep;177:38-46
pubmed: 27451032
J Leukoc Biol. 2007 Oct;82(4):887-93
pubmed: 17609339
Stem Cell Res Ther. 2017 Apr 26;8(1):100
pubmed: 28446224
Stem Cells. 2018 Apr;36(4):602-615
pubmed: 29341339
Cytometry A. 2018 Jan;93(1):32-49
pubmed: 28906582
Stem Cells. 2016 Sep;34(9):2393-406
pubmed: 27299700
Sci Rep. 2017 Mar 27;7(1):434
pubmed: 28348366
J Immunol Res. 2015;2015:752510
pubmed: 26000315
Sci Rep. 2014 Apr 02;4:4565
pubmed: 24691433
Stem Cell Res Ther. 2018 Apr 3;9(1):82
pubmed: 29615127
Stem Cells Transl Med. 2017 Dec;6(12):2173-2185
pubmed: 29076267
Stem Cell Res Ther. 2013 Jun 04;4(3):65
pubmed: 23734780
Immunology. 1989 Mar;66(3):376-83
pubmed: 2495247
Vet Immunol Immunopathol. 2018 Aug;202:25-30
pubmed: 30078595
Immunol Cell Biol. 2013 Jan;91(1):19-26
pubmed: 23090487
Biomaterials. 2015 Jan;37:124-33
pubmed: 25453943
Br J Pharmacol. 2000 Sep;131(1):152-9
pubmed: 10960082
Cytotherapy. 2003;5(6):485-9
pubmed: 14660044
Cell Immunol. 2004 Apr;228(2):99-109
pubmed: 15219461
Stem Cell Res Ther. 2018 Jan 17;9(1):11
pubmed: 29343288
Heliyon. 2018 Jun 06;4(6):e00642
pubmed: 30003150
Vet Immunol Immunopathol. 2018 May;199:22-31
pubmed: 29678226
Blood. 2003 May 1;101(9):3722-9
pubmed: 12506037
Stem Cells Dev. 2014 Jun 1;23(11):1217-32
pubmed: 24428376
J Clin Exp Hematop. 2010;50(2):79-89
pubmed: 21123965
Stem Cells Dev. 2014 Jun 1;23(11):1258-65
pubmed: 24438346
Cell Transplant. 2016 Dec 13;25(12):2199-2211
pubmed: 27392888
Blood. 2002 May 15;99(10):3838-43
pubmed: 11986244
Stem Cells. 2017 May;35(5):1416-1430
pubmed: 28233425
Gene. 2017 Sep 5;627:327-336
pubmed: 28600182
Stem Cell Res Ther. 2014 Jan 13;5(1):6
pubmed: 24418262
Cell Physiol Biochem. 2015;37(1):117-30
pubmed: 26303308
Sci Rep. 2016 Dec 02;6:38308
pubmed: 27910911
EBioMedicine. 2018 Feb;28:261-273
pubmed: 29366627
Stem Cell Res Ther. 2015 Aug 18;6:143
pubmed: 26282627
Vet Immunol Immunopathol. 2016 Mar;171:57-65
pubmed: 26964718
PLoS One. 2015 Apr 22;10(4):e0122954
pubmed: 25902064
Cytotherapy. 2016 Feb;18(2):151-9
pubmed: 26724220
J Immunol. 1986 Jan;136(1):186-92
pubmed: 3079606
Stem Cells Int. 2017;2017:8178643
pubmed: 28740516
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
PLoS One. 2015 May 01;10(5):e0124888
pubmed: 25933287
J Stem Cells Regen Med. 2017 Dec 18;13(2):62-74
pubmed: 29391751
Cell Transplant. 2010;19(6):667-79
pubmed: 20525442
Cytotherapy. 2017 Oct;19(10):1152-1166
pubmed: 28823421
Stem Cells Dev. 2017 Apr 1;26(7):503-511
pubmed: 27958776
Am J Transl Res. 2010 Jun 30;2(4):356-67
pubmed: 20733946
Transfus Med Hemother. 2009;36(6):383-387
pubmed: 21245969
Nat Immunol. 2007 Sep;8(9):931-41
pubmed: 17694059
J Immunol. 2013 Jan 15;190(2):565-77
pubmed: 23241891
Trends Mol Med. 2001 Jun;7(6):259-64
pubmed: 11378515
Tissue Eng Part A. 2011 Oct;17(19-20):2463-71
pubmed: 21554192
J Immunol. 2005 Aug 1;175(3):1483-90
pubmed: 16034085
Cell Transplant. 2016;25(1):109-24
pubmed: 25853993
Cell Med. 2012;4(1):1-11
pubmed: 23152950
Int J Mol Med. 2014 Sep;34(3):695-704
pubmed: 24970492
World J Stem Cells. 2014 Nov 26;6(5):526-39
pubmed: 25426250